Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Standard

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. / Hansson, Oskar; Lehmann, Sylvain; Otto, Markus; Zetterberg, Henrik; Lewczuk, Piotr.

I: Alzheimer's Research and Therapy, Vol. 11, Nr. 1, 22.04.2019, s. 1-15.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Harvard

APA

CBE

MLA

Vancouver

Author

Hansson, Oskar ; Lehmann, Sylvain ; Otto, Markus ; Zetterberg, Henrik ; Lewczuk, Piotr. / Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. I: Alzheimer's Research and Therapy. 2019 ; Vol. 11, Nr. 1. s. 1-15.

RIS

TY - JOUR

T1 - Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

AU - Hansson, Oskar

AU - Lehmann, Sylvain

AU - Otto, Markus

AU - Zetterberg, Henrik

AU - Lewczuk, Piotr

PY - 2019/4/22

Y1 - 2019/4/22

N2 - The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio) has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ42/40 ratio, rather than the absolute value of CSF Aβ42, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.

AB - The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio) has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ42/40 ratio, rather than the absolute value of CSF Aβ42, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.

KW - Alzheimer’s Disease

KW - Amyloidβ Peptides

KW - Aβ42/40 ratio

KW - Biomarkers

KW - Cerebrospinal Fluid

U2 - 10.1186/s13195-019-0485-0

DO - 10.1186/s13195-019-0485-0

M3 - Review article

VL - 11

SP - 1

EP - 15

JO - Alzheimer's Research & Therapy

T2 - Alzheimer's Research & Therapy

JF - Alzheimer's Research & Therapy

SN - 1758-9193

IS - 1

ER -